REFERENCES
1. Bacharier LB. Viral-induced wheezing episodes in preschool children:
approaches to therapy. Curr Opin Pulm Med 2010; 16: 31-5.
2. Bloomberg GR. Recurrent wheezing illness in preschool-aged children:
assessment and management in primary care practice. Postgrad Med 2009;
121: 48-55.
3. Brand PL, Baraldi E, Bisgaard H, Boner AL, Castro-Rodriguez JA,
Custovic A, et al. Definition, assessment and treatment of wheezing
disorders in preschool children: an evidence-based approach. Eur Respir
J 2008; 32: 1096-110.
4. Brodlie M, Gupta A, Rodriguez-Martinez CE, Castro-Rodriguez JA,
Ducharme FM and McKean MC. Leukotriene receptor antagonists as
maintenance or intermittent treatment in pre-school children with
episodic viral wheeze. Paediatr Respir Rev 2016; 17: 57-9.
5. Bhatt JM and Smyth AR. The management of pre-school wheeze. Paediatr
Respir Rev 2011; 12: 70-7.
6. Ducharme FM, Tse SM and Chauhan B. Diagnosis, management, and
prognosis of preschool wheeze. Lancet 2014; 383: 1593-604.
7. Haq I, Harris C, Taylor J, McKean MC and Brodlie M. Should we use
montelukast in wheezy children? Arch Dis Child 2017; 102: 997-8.
8. Schultz A and Brand PL. Episodic viral wheeze and multiple trigger
wheeze in preschool children: a useful distinction for clinicians?
Paediatr Respir Rev 2011; 12: 160-4.
9. Castro-Rodríguez JA, Holberg CJ, Wright AL and Martinez FD. A
clinical index to define risk of asthma in young children with recurrent
wheezing. Am J Respir Crit Care Med 2000; 162: 1403-6.
10. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and
Management of Asthma-Summary Report 2007. J Allergy Clin Immunol 2007;
120: S94-138.
11. Castro-Rodriguez JA. The Asthma Predictive Index: early diagnosis of
asthma. Curr Opin Allergy Clin Immunol 2011; 11: 157-61.
12. Bisgaard H, Zielen S, Garcia-Garcia ML, Johnston SL, Gilles L,
Menten J, et al. Montelukast reduces asthma exacerbations in 2- to
5-year-old children with intermittent asthma. Am J Respir Crit Care Med
2005; 171: 315-22.
13. Burman A. Question 2: Is there a role for Montelukast in the
management of viral-induced wheeze in preschool children? Arch Dis Child
2018; 103: 519-20.
14. Hussein HR, Gupta A, Broughton S, Ruiz G, Brathwaite N and Bossley
CJ. A meta-analysis of montelukast for recurrent wheeze in preschool
children. Eur J Pediatr 2017; 176: 963-9.
15. Kaiser SV, Huynh T, Bacharier LB, Rosenthal JL, Bakel LA, Parkin PC,
et al. Preventing Exacerbations in Preschoolers With Recurrent Wheeze: A
Meta-analysis. Pediatrics 2016; 137.
16. Guilbert TW, Morgan WJ, Zeiger RS, Bacharier LB, Boehmer SJ, Krawiec
M, et al. Atopic characteristics of children with recurrent wheezing at
high risk for the development of childhood asthma. J Allergy Clin
Immunol 2004; 114: 1282-7.
17. Hansen I, Klimek L, Mösges R and Hörmann K. Mediators of
inflammation in the early and the late phase of allergic rhinitis. Curr
Opin Allergy Clin Immunol 2004; 4: 159-63.
18. Bacharier LB, Phillips BR, Zeiger RS, Szefler SJ, Martinez FD,
Lemanske RF, Jr., et al. Episodic use of an inhaled corticosteroid or
leukotriene receptor antagonist in preschool children with
moderate-to-severe intermittent wheezing. J Allergy Clin Immunol 2008;
122: 1127-35.e8.
19. Brodlie M, Gupta A, Rodriguez-Martinez CE, Castro-Rodriguez JA,
Ducharme FM and McKean MC. Leukotriene receptor antagonists as
maintenance and intermittent therapy for episodic viral wheeze in
children. Cochrane Database Syst Rev 2015; 2015: CD008202.
20. Nwokoro C, Pandya H, Turner S, Eldridge S, Griffiths CJ, Vulliamy T,
et al. Intermittent montelukast in children aged 10 months to 5 years
with wheeze (WAIT trial): a multicentre, randomised, placebo-controlled
trial. Lancet Respir Med 2014; 2: 796-803.
21. Robertson CF, Price D, Henry R, Mellis C, Glasgow N, Fitzgerald D,
et al. Short-course montelukast for intermittent asthma in children: a
randomized controlled trial. Am J Respir Crit Care Med 2007; 175: 323-9.
22. Valovirta E, Boza ML, Robertson CF, Verbruggen N, Smugar SS, Nelsen
LM, et al. Intermittent or daily montelukast versus placebo for episodic
asthma in children. Ann Allergy Asthma Immunol 2011; 106: 518-26.
23. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello
N, et al. Montelukast, a leukotriene receptor antagonist, for the
treatment of persistent asthma in children aged 2 to 5 years. Pediatrics
2001; 108: E48.
24. Aigner L, Pietrantonio F, Bessa de Sousa DM, Michael J, Schuster D,
Reitsamer HA, et al. The Leukotriene Receptor Antagonist Montelukast as
a Potential COVID-19 Therapeutic. Front Mol Biosci 2020; 7: 610132.
25. Durdagi S, Avsar T, Orhan MD, Serhatli M, Balcioglu BK, Ozturk HU,
et al. The neutralization effect of Montelukast on SARS-CoV-2 is shown
by multiscale in silico simulations and combined in vitro studies.
bioRxiv 2020: 2020.12.26.424423.
26. Razi CH, Harmancı K, Abacı A, Özdemir O, Hızlı S, Renda R, et al.
The immunostimulant OM-85 BV prevents wheezing attacks in preschool
children. J Allergy Clin Immunol 2010; 126: 763-9.